Download PDF
kleintier konkret 2019; 22(01): 47-50
DOI: 10.1055/a-0815-7389
Newsletter
Georg Thieme Verlag KG Stuttgart · New York

Osteoarthritis beim Hund – Grapiprant als neue Therapieoption

Piprante wie Grapiprant (Galliprant®) bieten durch ihren selektiven Wirkansatz neue Potenziale für Hunde mit chronischen Gelenkerkrankungen
Stephan Neudeck
Further Information

Publication History

Publication Date:
27 February 2019 (online)

Also available at
    Permissions and Reprints All articles of this category

Der selektive EP4-Rezeptorantagonist Grapiprant ist ab 2019 als Galliprant® in Deutschland erhältlich. Damit steht Tierärzten neben den klassischen antiphlogistischen und analgetischen Wirkstoffen eine alternative Behandlungsoption mit selektivem Wirkmechanismus zur Verfügung.
 

  • Literatur

  • 1 Fox SM. Chronic Pain in Small Animal Medicine. London: Manson Publishing; 2010
    Google Scholar
  • 2 Johnston SA. Osteoarthritis: Joint anatomy, physiology, and pathobiology. Vet Clin North Am Small Anim Pract 1997; 27: 699-723
    CrossrefPubMedGoogle Scholar
  • 3 Brunnberg L, Waibl H, Lehmann J. Degenerative und entzündliche Gelenkerkrankungen. In: Brunnberg L, Waibl H, Lehmann J. Hrsg. Lahmheit beim Hund. Kleinmachnow: Procane Claudo Brunnberg; 2014: 457-490
    Google Scholar
  • 4 Aragon CL, Hofmeister EH, Budsberg SC. Systematic review of clinical trials of treatments for osteoarthritis in dogs. J Am Vet Med Assoc 2007; 230: 514-521
    CrossrefPubMedGoogle Scholar
  • 5 Kellgren JH, Samuel EP. The sensitivity and innervation of the articular capsule. J Bone and Joint Surg (Brit) 1950; 32: 84-92
    Google Scholar
  • 6 Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 2011; 63: A-BP
    Google Scholar
  • 7 KuKanich B, Bidgood T, Knesl O. Clinical pharmacology of nonsteroidal anti-inflammatory drugs in dogs. Vet Anaesth Analg 2012; 39: 69-90
    CrossrefPubMedGoogle Scholar
  • 8 Lin CR, Amaya F, Barrett L. et al. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 2006; 319: 1096-1103
    CrossrefPubMedGoogle Scholar
  • 9 Clark P, Rowland SE, Denis D. et al. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo [3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther 2008; 325: 425-434
    CrossrefPubMedGoogle Scholar
  • 10 Nakao K, Murase A, Ohshiro H. et al. CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 2007; 322: 686-694
    CrossrefPubMedGoogle Scholar
  • 11 Castleberry TA, Lu B, Smock SL. et al. Molecular cloning and functional characterization of the canine prostaglandin E2 receptor EP4 subtype. Prostaglandins Other Lipid Mediat 2001; 65: 167-187
    CrossrefPubMedGoogle Scholar
  • 12 Aoi M, Aihara E, Nakashima M. et al. Participation of prostaglandin E receptor EP4 subtype in duodenal bicarbonate secretion in rats. Am J Physiol Gastrointest Liver Physiol 2004; 287: G96-103
    CrossrefPubMedGoogle Scholar
  • 13 Larsen R, Hansen MB, Bindslev N. Duodenal secretion in humans mediated by the EP4 receptor subtype. Acta Physiol Scand 185: 2005; 133-140
    Google Scholar
  • 14 Takahashi S, Takeuchi K, Okabe S. EP4 receptor mediation of prostaglandin E2-stimulated mucus secretion by rabbit gastric epithelial cells. Biochem Pharmacol 1999; 58: 1997-2002
    CrossrefPubMedGoogle Scholar
  • 15 Hoshino T, Tsutsumi S, Tomisato W. et al. Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem 2003; 278: 12752-12758
    CrossrefPubMedGoogle Scholar
  • 16 Takeuchi K, Tanaka A, Kato S. et al. Effect of (S)-4-(1-(5-chloro-2-(4-fluorophenyoxy)benzamido) ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa. J Pharmacol Exp Ther 2007; 322: 903-912
    CrossrefPubMedGoogle Scholar
  • 17 Brown DC, Bell M, Rhodes L. Power of treatment success definitions when the Canine Brief Pain Inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis. Am J Vet Res 2013; 74: 1467-1473
    CrossrefPubMedGoogle Scholar
  • 18 Rausch-Derra L, Huebner M, Wofford J. et al. A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis. J Vet Intern Med 2016; 30: 756-763
    CrossrefPubMedGoogle Scholar
  • 19 Rausch-Derra LC, Huebner M, Rhodes L. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs. Am J Vet Res 2015; 76: 853-859
    CrossrefPubMedGoogle Scholar
  • 20 Monteiro-Steagall BP, Steagall PV, Lascelles BD. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. J Vet Intern Med 2013; 27: 1011-1019
    CrossrefPubMedGoogle Scholar